NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Bristol-Myers Squibb Company (NYSE:BMY), AAR Corp. (NYSE:AIR), Central Garden & Pet Company (NASDAQ:CENTA), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Tribune Media Company (NYSE:TRCO), and Civitas Solutions, Inc. (NYSE:CIVI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
BMY DOWNLOAD: http://Capital-Review.com/register/?so=BMY
AIR DOWNLOAD: http://Capital-Review.com/register/?so=AIR
CENTA DOWNLOAD: http://Capital-Review.com/register/?so=CENTA
ALXN DOWNLOAD: http://Capital-Review.com/register/?so=ALXN
TRCO DOWNLOAD: http://Capital-Review.com/register/?so=TRCO
CIVI DOWNLOAD: http://Capital-Review.com/register/?so=CIVI
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine Bristol-Myers Squibb Company (NYSE:BMY), AAR Corp. (NYSE:AIR), Central Garden & Pet Company (NASDAQ:CENTA), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Tribune Media Company (NYSE:TRCO), and Civitas Solutions, Inc. (NYSE:CIVI) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 4th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
BRISTOL-MYERS SQUIBB COMPANY (BMY) REPORT OVERVIEW
Bristol-Myers Squibb's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Bristol-Myers Squibb reported revenue of $5,973.00MM vs $5,449.00MM (up 9.62%) and analysts estimated basic earnings per share $0.71 vs -$1.42. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Bristol-Myers Squibb reported revenue of $22,561.00MM vs $20,776.00MM (up 8.59%) and analysts estimated basic earnings per share $3.01 vs $0.61 (up 393.44%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.94. The estimated EPS forecast for the next fiscal year is $4.22 and is expected to report on January 23rd, 2020.
To read the full Bristol-Myers Squibb Company (BMY) report, download it here: http://Capital-Review.com/register/?so=BMY
-----------------------------------------
AAR CORP. (AIR) REPORT OVERVIEW
AAR's Recent Financial Performance
For the three months ended November 30th, 2018 vs November 30th, 2017, AAR reported revenue of $493.30MM vs $420.60MM (up 17.28%) and analysts estimated basic earnings per share $0.20 vs -$0.66. For the twelve months ended May 31st, 2018 vs May 31st, 2017, AAR reported revenue of $1,748.30MM vs $1,590.80MM (up 9.90%) and analysts estimated basic earnings per share $0.44 vs $1.66 (down 73.49%). Analysts expect earnings to be released on March 19th, 2019. The report will be for the fiscal period ending February 28th, 2019. Reported EPS for the same quarter last year was $0.49. The estimated EPS forecast for the next fiscal year is $2.85 and is expected to report on July 9th, 2019.
To read the full AAR Corp. (AIR) report, download it here: http://Capital-Review.com/register/?so=AIR
-----------------------------------------
CENTRAL GARDEN & PET COMPANY (CENTA) REPORT OVERVIEW
Central Garden & Pet's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Central Garden & Pet reported revenue of $461.99MM vs $442.01MM (up 4.52%) and analysts estimated basic earnings per share $0.03 vs $0.52 (down 94.23%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Central Garden & Pet reported revenue of $2,215.36MM vs $2,054.48MM (up 7.83%) and analysts estimated basic earnings per share $2.39 vs $1.57 (up 52.23%). Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.86. The estimated EPS forecast for the next fiscal year is $1.98 and is expected to report on November 26th, 2019.
To read the full Central Garden & Pet Company (CENTA) report, download it here: http://Capital-Review.com/register/?so=CENTA
-----------------------------------------
ALEXION PHARMACEUTICALS, INC. (ALXN) REPORT OVERVIEW
Alexion Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Alexion Pharmaceuticals reported revenue of $1,128.80MM vs $909.70MM (up 24.08%) and basic earnings per share -$0.20 vs $0.13. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Alexion Pharmaceuticals reported revenue of $4,131.20MM vs $3,551.10MM (up 16.34%) and analysts estimated basic earnings per share $0.35 vs $1.98 (down 82.32%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.53. The estimated EPS forecast for the next fiscal year is $9.27 and is expected to report on February 3rd, 2020.
To read the full Alexion Pharmaceuticals, Inc. (ALXN) report, download it here: http://Capital-Review.com/register/?so=ALXN
-----------------------------------------
TRIBUNE MEDIA COMPANY (TRCO) REPORT OVERVIEW
Tribune Media's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Tribune Media reported revenue of $498.01MM vs $450.53MM (up 10.54%) and analysts estimated basic earnings per share $0.62 vs -$0.21. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Tribune Media reported revenue of $1,848.96MM vs $1,947.93MM (down 5.08%) and analysts estimated basic earnings per share $2.23 vs $0.16 (up 1,293.75%). Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.51. The estimated EPS forecast for the next fiscal year is $3.46 and is expected to report on March 6th, 2020.
To read the full Tribune Media Company (TRCO) report, download it here: http://Capital-Review.com/register/?so=TRCO
-----------------------------------------
CIVITAS SOLUTIONS, INC. (CIVI) REPORT OVERVIEW
Civitas Solutions' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Civitas Solutions reported revenue of $406.63MM vs $395.42MM (up 2.84%) and analysts estimated basic earnings per share $0.18 vs $0.25 (down 28.00%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Civitas Solutions reported revenue of $1,602.20MM vs $1,474.51MM (up 8.66%) and analysts estimated basic earnings per share $0.40 vs $0.17 (up 135.29%). Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.33.
To read the full Civitas Solutions, Inc. (CIVI) report, download it here: http://Capital-Review.com/register/?so=CIVI
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.